Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Neurological channelopathies.

Literature DB >> 9552942

Neurological channelopathies.

M R Rose.

Abstract

Entities: Disease

Mesh：

Substances：
Ion Channels

Year: 1998 PMID： 9552942 PMCID： PMC1112934 DOI： 10.1136/bmj.316.7138.1104

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

13 in total

1. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial.

Authors: C T Bever; P A Anderson; J Leslie; H S Panitch; S Dhib-Jalbut; O A Khan; R Milo; J R Hebel; K L Conway; E Katz; K P Johnson
Journal: Neurology Date: 1996-12 Impact factor: 9.910

2. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.

Authors: R A Ophoff; G M Terwindt; M N Vergouwe; R van Eijk; P J Oefner; S M Hoffman; J E Lamerdin; H W Mohrenweiser; D E Bulman; M Ferrari; J Haan; D Lindhout; G J van Ommen; M H Hofker; M D Ferrari; R R Frants
Journal: Cell Date: 1996-11-01 Impact factor: 41.582

3. Identification of two new KCNA1 mutations in episodic ataxia/myokymia families.

Authors: D L Browne; E R Brunt; R C Griggs; J G Nutt; S T Gancher; E A Smith; M Litt
Journal: Hum Mol Genet Date: 1995-09 Impact factor: 6.150

4. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel.

Authors: O Zhuchenko; J Bailey; P Bonnen; T Ashizawa; D W Stockton; C Amos; W B Dobyns; S H Subramony; H Y Zoghbi; C C Lee
Journal: Nat Genet Date: 1997-01 Impact factor: 38.330

5. A gene for autosomal dominant paroxysmal choreoathetosis/spasticity (CSE) maps to the vicinity of a potassium channel gene cluster on chromosome 1p, probably within 2 cM between D1S443 and D1S197.

Authors: G Auburger; T Ratzlaff; A Lunkes; H W Nelles; B Leube; F Binkofski; H Kugel; W Heindel; R Seitz; R Benecke; O W Witte; T Voit
Journal: Genomics Date: 1996-01-01 Impact factor: 5.736

6. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma.

Authors: S D Meriney; S C Hulsizer; V A Lennon; A D Grinnell
Journal: Ann Neurol Date: 1996-11 Impact factor: 10.422

7. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.

Authors: K M McEvoy; A J Windebank; J R Daube; P A Low
Journal: N Engl J Med Date: 1989-12-07 Impact factor: 91.245

8. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy.

Authors: O K Steinlein; J C Mulley; P Propping; R H Wallace; H A Phillips; G R Sutherland; I E Scheffer; S F Berkovic
Journal: Nat Genet Date: 1995-10 Impact factor: 38.330

9. The acute paralysis in Guillain-Barré syndrome is related to a Na+ channel blocking factor in the cerebrospinal fluid.

Authors: H Brinkmeier; K H Wollinsky; P J Hülser; M J Seewald; H H Mehrkens; H H Kornhuber; R Rüdel
Journal: Pflugers Arch Date: 1992-09 Impact factor: 3.657

10. Factors in the cerebrospinal fluid of multiple sclerosis patients interfering with voltage-dependent sodium channels.

Authors: H Brinkmeier; K H Wollinsky; M J Seewald; P J Hülser; H H Mehrkens; H H Kornhuber; R Rüdel
Journal: Neurosci Lett Date: 1993-06-25 Impact factor: 3.046

4 in total

Review 4. Molecular Choreography and Structure of Ca²⁺ Release-Activated Ca²⁺ (CRAC) and K_Ca2+ Channels and Their Relevance in Disease with Special Focus on Cancer.

Authors: Adéla Tiffner; Isabella Derler
Journal: Membranes (Basel) Date: 2020-12-15

4 in total

Neurological channelopathies.

1. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial.

2. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.

3. Identification of two new KCNA1 mutations in episodic ataxia/myokymia families.

4. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel.

5. A gene for autosomal dominant paroxysmal choreoathetosis/spasticity (CSE) maps to the vicinity of a potassium channel gene cluster on chromosome 1p, probably within 2 cM between D1S443 and D1S197.

6. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma.

7. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.

8. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy.

9. The acute paralysis in Guillain-Barré syndrome is related to a Na+ channel blocking factor in the cerebrospinal fluid.

10. Factors in the cerebrospinal fluid of multiple sclerosis patients interfering with voltage-dependent sodium channels.

1. Nanotechnology for Neuroscience: Promising Approaches for Diagnostics, Therapeutics and Brain Activity Mapping.

2. A cell cycle alteration precedes apoptosis of granule cell precursors in the weaver mouse cerebellum.

3. Synaptic conversion of chloride-dependent synapses in spinal nociceptive circuits: roles in neuropathic pain.

Review 4. Molecular Choreography and Structure of Ca²⁺ Release-Activated Ca²⁺ (CRAC) and K_Ca2+ Channels and Their Relevance in Disease with Special Focus on Cancer.

Review 4. Molecular Choreography and Structure of Ca2+ Release-Activated Ca2+ (CRAC) and KCa2+ Channels and Their Relevance in Disease with Special Focus on Cancer.

Review 4. Molecular Choreography and Structure of Ca²⁺ Release-Activated Ca²⁺ (CRAC) and K_Ca2+ Channels and Their Relevance in Disease with Special Focus on Cancer.